Tove Olafsen

City of Hope

Papers

1

Total Citations

18

H-Index

1

About

Tove Olafsen is a pioneering molecular imaging scientist whose work bridges the gap between antibody engineering and surgical oncology. Her research focuses on developing novel protein-based imaging agents, particularly minibodies and antibody fragments, for targeted molecular imaging of cancer. Olafsen's major contributions include the design and clinical translation of engineered antibody fragments that enable real-time visualization of tumors during surgery. Her landmark 2024 first-in-human study of the PSMA-targeting minibody IR800-IAB2M (18 citations) demonstrated the feasibility of molecularly guided fluorescence imaging during radical prostatectomy, allowing surgeons to visualize prostate cancer tissue in real time. This work builds on her extensive career developing immunoPET and optical imaging agents for prostate and other cancers. Olafsen's impact is evident in her sustained contributions to theranostics, where her engineered minibodies have been widely adopted for both diagnostic imaging and intraoperative guidance. Her achievements include pioneering the clinical translation of antibody fragment-based imaging agents, advancing the field of image-guided surgery, and establishing new paradigms for molecularly targeted intraoperative fluorescence guidance in oncology.

Research Focus

Key Achievements

1
H-Index
1
Papers
18
Total Citations
18
Avg Citations/Paper
🏆 Most Cited Paper
First-in-man study of the PSMA Minibody IR800-IAB2M for molecularly targeted intraoperative fluorescence guidance during radical prostatectomy
18 citations · 2024
📈 Most Prolific Year: 2024 (1 Papers)
🤝 Key Collaborators: 27
🏛 Institutions: City of Hope

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 12 days ago